Cesca is a leading regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics.
Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology.
Cesca is also leveraging its proprietary AutoXpress® technology platform to develop an automated, functionally-closed CAR-TXpress platform that addresses cellular manufacturing needs in the immuno-oncology field.
November 15, 2019
RegMed Investors’ (RMi) closing bell: indexes made fresh new highs as “our” universe got high on increasing value
November 15, 2019
RegMed Investors’ (RMi) pre-open: I want to get higher, the sector said
November 14, 2019
RegMed Investors’ (RMi) closing bell: four (4) flopping sessions in a row for my comparable universe
November 14, 2019
RegMed Investors’ (RMi) pre-open: US futures point to lower open, “our” universe deserves a bounce
November 13, 2019
RegMed Investors’ (RMi) closing bell: lower than low volume is a factor as the cell and gene therapy sector bottoms kissing the floor, again
November 12, 2019
RegMed Investors’ (RMi) closing bell: a lot of pitches and many strikes today
November 12, 2019
RegMed Investors’ (RMi) pre-open: we need to plug the dike of the oversold spilling over
November 12, 2019
RegMed Investors’ (RMi) closing bell: back to being oversold on low volume
November 8, 2019
RegMed Investors’ (RMi) closing bell: the month rocks back and forth
November 7, 2019
RegMed Investors’ (RMi) closing bell: the sector bounced to the upside
35 companies, 1 interpreter!
Insight, foresight and recommendation
Cesca Therapeutics (KOOL) – January '18 opened at $3.10 and it's beed downhill until February at $2.75 with some upside to $2.95 on 2/16. NOT a believer ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors